Steven E. Hyman

ORCID: 0000-0002-3628-2359
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurotransmitter Receptor Influence on Behavior
  • Neuroscience and Neuropharmacology Research
  • Mental Health and Psychiatry
  • Receptor Mechanisms and Signaling
  • Genetics and Neurodevelopmental Disorders
  • Genetic Associations and Epidemiology
  • Autism Spectrum Disorder Research
  • Schizophrenia research and treatment
  • Genomics and Rare Diseases
  • Mental Health Research Topics
  • Neuroethics, Human Enhancement, Biomedical Innovations
  • Memory and Neural Mechanisms
  • Personality Disorders and Psychopathology
  • Neuropeptides and Animal Physiology
  • Functional Brain Connectivity Studies
  • Stress Responses and Cortisol
  • Bioinformatics and Genomic Networks
  • Child and Adolescent Psychosocial and Emotional Development
  • Treatment of Major Depression
  • Bipolar Disorder and Treatment
  • Health, Environment, Cognitive Aging
  • Mental Health Treatment and Access
  • Attention Deficit Hyperactivity Disorder
  • Neuroendocrine regulation and behavior
  • Health Systems, Economic Evaluations, Quality of Life

Harvard University
2014-2024

Broad Institute
2015-2024

Massachusetts Institute of Technology
2012-2024

Stanley Center for Psychiatric Research
2024

Harvard University Press
2004-2023

Stanley Foundation
2023

Harvard Stem Cell Institute
2011-2022

Massachusetts General Hospital
1987-2021

University of Southern California
2006-2021

University of California, Los Angeles
2021

Following approval of the ICD‐11 by World Health Assembly in May 2019, Organization (WHO) member states will transition from ICD‐10 to ICD‐11, with reporting health statistics based on new system begin January 1, 2022. The WHO Department Mental and Substance Abuse publish Clinical Descriptions Diagnostic Guidelines (CDDG) for Mental, Behavioural Neurodevelopmental Disorders following ICD‐11’s approval. development CDDG over past decade, principles clinical utility global applicability, has...

10.1002/wps.20611 article EN World Psychiatry 2019-01-02

Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3′,5′-monophosphate–regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all that receive dopaminergic input, converted response to dopamine into potent protein phosphatase inhibitor. Mice generated contain targeted disruption of DARPP-32 gene showed profound deficits their molecular, electrophysiological, behavioral responses dopamine, drugs abuse, antipsychotic medication....

10.1126/science.281.5378.838 article EN Science 1998-08-07

Chronic treatment of rats with cocaine leads to long-term biochemical changes in the nucleus accumbens (NAc), a brain region implicated mediating reinforcing effects and other drugs abuse. Immediate early genes (IEGs) their protein products appear play an important role transducing extracellular stimuli into altered patterns cellular gene expression and, therefore, functioning. We therefore examined mRNA levels for IEGs c-fos, c-jun, fosB, junB, zif268 NAc treated acutely chronically...

10.1073/pnas.89.13.5764 article EN Proceedings of the National Academy of Sciences 1992-07-01

The World Health Organization is in the process of preparing eleventh revision International Classification Diseases (ICD-11), scheduled for presentation to Assembly approval 2017. Advisory Group Revision ICD-10 Mental and Behavioural Disorders made improvement clinical utility an organizing priority revision. uneven nature diagnostic information included Clinical Descriptions Diagnostic Guidelines (CDDG), especially with respect differential diagnosis, a major shortcoming terms its...

10.1002/wps.20189 article EN World Psychiatry 2015-02-01

Drug discovery is at a near standstill for psychiatric disorders such as schizophrenia, bipolar disorder, and depression.

10.1126/scitranslmed.3003142 article EN Science Translational Medicine 2012-10-10
Coming Soon ...